Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:13 AM
Ignite Modification Date:
2025-12-25 @ 4:13 AM
NCT ID:
NCT02759120
Eligibility Criteria:
Inclusion Criteria:
1. ≥ 40 years of age
2. Diagnosed with idiopathic pulmonary fibrosis (IPF) by enrolling investigator
3. Signed informed consent
Exclusion Criteria:
1. Received antimicrobial therapy in the past 30 days
2. Contraindicated for antibiotic therapy, including but not exclusive to:
1. Allergy or intolerance to both tetracyclines AND trimethoprim, sulfonamides or their combination
2. Allergy or intolerance to tetracyclines AND known potassium level \> 5 mEq/L in the past 90 days.
* If the enrolling physician feels the potassium level has normalized, documentation to that effect must be provided.
3. Allergy or intolerance to tetracyclines AND concomitant use of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), potassium sparing diuretic, dofetilide, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide
4. Allergy or intolerance to tetracyclines AND known glucose-6-phosphate dehydrogenase deficiency
5. Allergy or intolerance to tetracyclines AND untreated folate or B12 deficiency
6. Allergy or intolerance to tetracyclines AND known renal insufficiency (defined as a glomerular filtration rate (GFR) \< 30 ml within the previous 90 days)
* If the enrolling physician feels the renal dysfunction has resolved, documentation to that effect must be provided.
3. Pregnant or anticipate becoming pregnant
4. Use of an investigational study agent for IPF therapy within the past 30 days, or an IV infusion with a half-life of four (4) weeks.
5. Concomitant immunosuppression with azathioprine, mycophenolate, cyclophosphamide, or cyclosporine.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT02759120
Study Brief:
Protocol Section:
NCT02759120